Barutçuoglu B, Parildar Z, Mutaf I, Habif S, Bayindir O
Department of Clinical Biochemistry, Ege University Faculty of Medicine, Izmir, Turkey.
Clin Lab Haematol. 2003 Aug;25(4):271-4. doi: 10.1046/j.1365-2257.2003.00524.x.
We report the case of a patient with IgG multiple myeloma and pseudohyperphosphatemia. The patient had no clinical features of hyperphosphatemia. Subsequent investigations demonstrated that this hyperphosphatemia was spurious and was caused by a high concentration of the paraprotein. Deproteinization of the serum samples by sulfosalicylic acid resulted in normalization of the elevated phosphate values. This pseudohyperphosphatemia resulted from an increase in optic density because of interference between monoclonal immunoglobulin and the molybdic reagent used to determine phosphate in serum. These data indicate that the finding of marked hyperphosphatemia in multiple myeloma patients should always prompt an assay carried out on a deproteinized sample. In addition, knowledge of this phenomenon may avoid confusion, unnecessary testing and obviate confusion in the clinical evaluation of patients with multiple myeloma.
我们报告了一例患有IgG型多发性骨髓瘤和假性高磷血症的患者。该患者没有高磷血症的临床特征。随后的检查表明，这种高磷血症是假性的，是由副蛋白浓度过高引起的。用磺基水杨酸对血清样本进行脱蛋白处理后，升高的磷酸盐值恢复正常。这种假性高磷血症是由于单克隆免疫球蛋白与用于测定血清中磷酸盐的钼试剂之间的干扰导致光密度增加所致。这些数据表明，在多发性骨髓瘤患者中发现明显的高磷血症时，应始终对脱蛋白样本进行检测。此外，了解这一现象可避免在多发性骨髓瘤患者的临床评估中出现混淆、不必要的检查。
